New UK Pathway Use Has ‘Far Exceeded Expectations’

Early/Mid-Development Stage Drugs Accounted For Most 1st-Year Requests

Oncology products accounted for the largest proportion of requests for a UK “innovation passport” last year, with a wide variety of drug sponsors deciding to use the new ILAP, according to the UK regulator, the MHRA.

Innovation letters — ILAP spells a new era in getting innovative medicines to patients • Source: Alamy

The number of applications to use the UK’s Innovative Licensing and Access Pathway (ILAP) far exceeded expectations in its first year of operation. That's according to Daniel O’Connor of the UK regulator, the MHRA, which operates the new scheme.

A total of 76 requests for an “innovation passport” were received last year following the launch of ILAP on at the beginning of 2021. “We were expecting around 30 applications...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

EU CHMP Opinions And MAA Updates

28 May 2025

• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

EMA: ‘Sad To See’ Member States Against Patient Engagement Under EU Pharma Reform

27 May 2025

• By Eliza Slawther

The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

27 May 2025

• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

27 May 2025

• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.